Capricor Therapeutics Faces Class Action Lawsuit Over Investor Losses
Pomerantz Law Firm has filed a class action lawsuit against Capricor Therapeutics, Inc. Investors who have incurred losses are advised to contact the firm regarding upcoming deadlines.
Pomerantz Law Firm announced it has filed a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of its shareholders. The suit alleges that the company made misleading statements or omissions that impacted investors.
The lawsuit targets investors who purchased Capricor securities during a specific period and subsequently suffered financial losses. Potential class members are urged to contact Pomerantz Law Firm to learn more about their rights and the legal proceedings.
Key deadlines are approaching for investors wishing to participate in the class action. Specific details regarding the filing period and other relevant dates can be obtained directly from the law firm. Capricor Therapeutics has not yet publicly responded to the lawsuit.